We have entered a new era for patients with mRCC with multiple treatment options including VEGF(Vascular Endothelial Growth Factor)-, MET(Mesenchymal-eptihelial Transition)-, AXL(AXL-Rezeptortyrosinkinase)-, mTOR(mechanistic Target of …
Autoren:
OÄ. Dr. Jasmin Terzic, Univ.-Prof. Dr. med. univ. Thomas Bauernhofer
Human papilloma virus (HPV) is a DNA virus consisting of approximately 8000 base pairs. HPV represents the most common sexually transmitted infection worldwide. Around 200 different genotypes exist. They are distinguished into low- and high-risk …
This article intends to summarize personal highlights from the 2019 ASCO (American Society of Clinical Oncology) Annual meeting. The article does not aim to offer a comprehensive summary of the 1642 abstracts presented, but rather aims to …
Surgical resection of RCC should be the aim for cure of localized or locally advanced RCC, either by partial or radical nephrectomy, depending on tumor size and patient’s performance status. In cT1 stages partial nephrectomy is recommended. In …
Autoren:
MD Sebastian Lenart, Ingrid Berger, Nikolaus Hartig, Stephan Madersbacher, Anton Ponholzer
The introduction of immune checkpoint inhibitors has further improved response and survival rates in patients with metastatic renal cell carcinoma. In this context, the most promising trial results in the past 12 months include KEYNOTE 426 and the …
Clinical presentation, vascular complications, and survival among a 90-patient cohort from a single center
Epidemiology of polycythemia vera (PV) is derived from cohort studies in Western populations. PV studies in the Latin population are limited and have described a lower prevalence of JAK2 mutation. A retrospective cohort of 90 Mexican patients from …
Autoren:
Antonio Olivas-Martinez, Olga Barrales-Benítez, Daniel Montante-Montes-de-Oca, Diana Aguilar-León, Hilda Elizeth Hernández-Juárez, Elena Tuna-Aguilar
Chimeric antigen receptor (CAR) T cells are genetically engineered cells containing fusion proteins combining an extracellular epitope-specific binding domain, a transmembrane and signaling domains of the T cell receptor. The CD19-CAR T cell …
The treatment landscape of metastatic renal cell cancer (mRCC) is rapidly evolving. To date in 2019 twelve drugs are licensed for this indication, two more drugs are awaited to be introduced into our portfolio of treatment options by the end of …
A substantial increase in the number of elderly patients with muscle invasive bladder cancer (MIBC) is expected in upcoming years due to demographic changes and the peak incidence of bladder cancer in the 8th decade of life. The management of …
At the 2019 ASCO (American Society of Clinical Oncology) Annual Meeting, several interesting trial results were presented in the field of HER2-positive metastatic breast cancer. The end-of-study analysis of the pivotal CLEOPATRA trial indicated an …
The optimal surveillance strategy in renal cell carcinoma after curative resection or ablation is a field of ongoing research. This review discusses the evidence behind routine follow up, duration of follow up, imaging modality and intervals as …
Although several large clinical trials have been conducted in order to investigate targeted inhibition of several molecular pathways in gastric cancer, only a limited number of targeted therapies have been introduced in clinical routine. Besides …
Autoren:
MD Hannah Christina Puhr, MD, PhD Aysegül Ilhan-Mutlu
New targeted therapies for patients with non small cell lung cancer were presented at this year’s ASCO. EGFR exon 20 insertions might soon be treatable with TAK-788, which showed an objective response rate (ORR) of between 25 and 56% with a …
Autoren:
M.D., Ph.D. Romana E. Wass, M.D. David Lang, M.D. Bernd Lamprecht, M.D. Michael Studnicka
During the last 30 years the developments in small cell lung cancer (SCLC) have been extremely scarce. Concurrent chemo-radiation associated with prophylactic cranial irradiation in case of complete clinical remission is standard in limited …
The purpose of this observational study was to determine the prevalence of comorbid conditions in cancer patients with solid tumours selected for specific treatment at 12 divisions of medical oncology in Austria. Data from 1137 patients were …
Autoren:
MDPhD Assoc. Prof. Marija Balic, Wolfgang Hilbe, Sylvia Gusel, Michael Fiegl, Heinz Ludwig, Beate Mayrbäurl, Josef Thaler, Hellmut Samonigg, Karin Hegenbarth, Florian Eisner, Brigitte Mlineritsch, Richard Greil, Maria Johanna Schandl, Ansgar Weltermann, Andreas Petzer, David Fuchs, Wolfgang Stangl, Peter Krippl, Reinhard Stauder, Herbert Stöger
Presentation highlights from the ASCO 2019 Congress
Three important oral presentations from the ASCO 2019 congress concerning advanced and metastatic urothelial carcinoma of the urinary bladder and the upper tract are highlighted and their potential clinical implications for the improvement of …
Autoren:
MD Assoc. Prof. Georg C. Hutterer, MD Assoc. Prof. Martin Pichler
A large number of medical societies have issued recommendations for follow-up after primary treatment for early breast cancer, which mostly differ only in the details. The central statement in all of these guidelines has been based on two studies …
Neoadjuvant cisplatin-based chemotherapy is standard treatment for muscle-invasive bladder cancer before radical cystectomy (RC). Despite level 1 evidence demonstrating an overall survival benefit for patients undergoing RC after neoadjuvant …
Autoren:
Stephan Brönimann, David D’Andrea, Shahrokh F. Shariat, MD Kilian M. Gust
Early stage HER2-positive cancer outcomes have been substantially improved over the last two decades, but there is still some potential for improvement. Several studies on the preoperative/postoperative treatment of HER2-positive breast cancer …
To date, intravesical instillation of Bacillus Calmette–Guérin (BCG) is the standard adjuvant treatment for most intermediate- and all high-risk bladder nonmuscle invasive urothelial carcinomas (NMIBC) after complete transurethral resection.
Autoren:
Stephan Brönimann, Shahrokh F. Shariat, Melanie R. Hassler